Surgery for stage IIIA-N2 non-small cell lung cancer: the jury is still out!
作者信息
Berzenji Lawek, Beckers Paul, Van Schil Paul E
机构信息
Department of Thoracic and Vascular Surgery, Antwerp University Hospital and Antwerp University, Belgium.
出版信息
J Thorac Dis. 2019 May;11(Suppl 9):S1153-S1156. doi: 10.21037/jtd.2019.04.36.
Abstract
摘要
相似文献
1
Surgery for stage IIIA-N2 non-small cell lung cancer: the jury is still out!ⅢA-N2期非小细胞肺癌的手术治疗：尚无定论！
J Thorac Dis. 2019 May;11(Suppl 9):S1153-S1156. doi: 10.21037/jtd.2019.04.36.
2
[Survival Analysis of 121 Stage N2-IIIa Non-small Cell Lung Cancer Patients
Treated with Surgery].121例接受手术治疗的N2-IIIa期非小细胞肺癌患者的生存分析
Zhongguo Fei Ai Za Zhi. 2015 Aug;18(8):505-11. doi: 10.3779/j.issn.1009-3419.2015.08.06.
3
Role of surgery in N2 NSCLC: pros.手术在N2期非小细胞肺癌中的作用：优势
Jpn J Clin Oncol. 2016 Dec;46(12):1168-1173. doi: 10.1093/jjco/hyw125. Epub 2016 Sep 21.
4
Prognostic Significance of the Number of Metastatic pN2 Lymph Nodes in Stage IIIA-N2 Non-Small-Cell Lung Cancer After Curative Resection.III A-N2期非小细胞肺癌根治性切除术后转移pN2淋巴结数量的预后意义
Clin Lung Cancer. 2015 Nov;16(6):e203-12. doi: 10.1016/j.cllc.2015.04.004. Epub 2015 Apr 23.
5
[Correlation between Lymph Node Ratio and Clinicopathological Features and Prognosis of IIIa-N2 Non-small Cell Lung Cancer].[Ⅲa-N2期非小细胞肺癌淋巴结比值与临床病理特征及预后的相关性]
Zhongguo Fei Ai Za Zhi. 2019 Nov 20;22(11):702-708. doi: 10.3779/j.issn.1009-3419.2019.11.04.
6
Prognostic Value of Tumor Size in Resected Stage IIIA-N2 Non-Small-Cell Lung Cancer.肿瘤大小对ⅢA-N2期非小细胞肺癌切除术后的预后价值
J Clin Med. 2020 May 1;9(5):1307. doi: 10.3390/jcm9051307.
7
The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.完全切除术后接受辅助化疗的 IIIA/N2 期非小细胞肺癌患者中 PORT 和 EGFR 突变状态的预后作用。
Pathol Oncol Res. 2021 Aug 10;27:1609898. doi: 10.3389/pore.2021.1609898. eCollection 2021.
8
[Review on Treatment Modalities for Resectable IIIa/N2 Non-small Cell Lung Cancer].[可切除的 IIIa/N2 期非小细胞肺癌治疗方式综述]
Zhongguo Fei Ai Za Zhi. 2019 Feb 20;22(2):111-117. doi: 10.3779/j.issn.1009-3419.2019.02.06.
9
Role of surgery for stage IIIA-N2 non-small cell lung cancer.IIIA-N2 期非小细胞肺癌的手术治疗作用。
Thorac Cancer. 2011 Aug;2(3):90-94. doi: 10.1111/j.1759-7714.2011.00048.x.
10
The prognostic significance of multiple station N2 in patients with surgically resected stage IIIA N2 non-small cell lung cancer.手术切除的IIIA期N2非小细胞肺癌患者多站N2的预后意义
J Korean Med Sci. 2008 Aug;23(4):604-8. doi: 10.3346/jkms.2008.23.4.604.
引用本文的文献
1
Evaluation of mediastinoscopy in mediastinal lymph node staging for non-small-cell lung cancer.纵隔镜在非小细胞肺癌纵隔淋巴结分期中的评价。
Interact Cardiovasc Thorac Surg. 2021 Jan 22;32(2):270-275. doi: 10.1093/icvts/ivaa263.
本文引用的文献
1
Occult stage IIIA-N2 patients have excellent overall survival with initial surgery.隐匿性IIIA-N2期患者接受初始手术后总体生存率良好。
J Thorac Dis. 2018 Dec;10(12):6670-6676. doi: 10.21037/jtd.2018.10.94.
2
The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis.IIIaN2 期非小细胞肺癌的最佳治疗方法：网状荟萃分析。
Ann Thorac Surg. 2019 Jun;107(6):1866-1875. doi: 10.1016/j.athoracsur.2018.11.024. Epub 2018 Dec 14.
3
Long term and disease-free survival following surgical resection of occult N2 lung cancer.隐匿性N2期肺癌手术切除后的长期无病生存
J Thorac Dis. 2018 Aug;10(8):4806-4811. doi: 10.21037/jtd.2018.07.125.
4
Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.诱导放化疗（50Gy），然后切除，用于 IIIA-N2 期非小细胞肺癌。
Ann Thorac Surg. 2018 Oct;106(4):1018-1024. doi: 10.1016/j.athoracsur.2018.05.027. Epub 2018 Jun 8.
5
Surgical Management of Stage IIIA Non-Small Cell Lung Cancer.ⅢA期非小细胞肺癌的外科治疗
Front Oncol. 2017 Oct 26;7:249. doi: 10.3389/fonc.2017.00249. eCollection 2017.
6
Salvage Surgery After Definitive Chemoradiotherapy for Non-small Cell Lung Cancer.非小细胞肺癌根治性放化疗后的挽救性手术
Semin Thorac Cardiovasc Surg. 2017;29(2):233-241. doi: 10.1053/j.semtcvs.2017.02.001. Epub 2017 Feb 24.
7
Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC) - a cumulative meta-analysis of the randomized evidence.III期非小细胞肺癌（NSCLC）多模式治疗中确定性放化疗与手术的比较——随机证据的累积荟萃分析
Oncotarget. 2017 Jun 20;8(25):41670-41678. doi: 10.18632/oncotarget.16471.
8
Management of Stage IIIA (N2) Non-Small Cell Lung Cancer.ⅢA期（N2）非小细胞肺癌的管理
Thorac Surg Clin. 2016 Aug;26(3):271-85. doi: 10.1016/j.thorsurg.2016.04.001.
9
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer.国际肺癌研究协会肺癌分期项目：对即将发布的第 8 版肺癌 TNM 分类中 N 描述符修订的建议。
J Thorac Oncol. 2015 Dec;10(12):1675-84. doi: 10.1097/JTO.0000000000000678.
10
Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).诱导化疗和同期放化疗后可切除 IIIA(N2)和部分 IIIB 期非小细胞肺癌患者的手术与根治性同期放化疗增敏的 III 期研究（ESPATUE）
J Clin Oncol. 2015 Dec 10;33(35):4194-201. doi: 10.1200/JCO.2015.62.6812. Epub 2015 Nov 2.
Zotero 插件